At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk Factors
In Brief
A Phase 3 clinical trial evaluating Combination Therapy, Monotherapy obicetrapib, and 4 other interventions for Dyslipidemias and 4 related conditions. Completed, enrolled 407 participants across 45 sites.
Detailed Summary
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Study Details
Timeline
Interventions
tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
tablet; 10mg obicetrapib
capsule; 10mg ezetimibe
tablet; no active ingredient
tablet; no active ingredient
capsule; no active ingredient